Table 3.

Meta-analysis Results

	Subgroup	No. of Estimatesa	No. of Lesions	No. of Malignant Melanoma	Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	sROC Area (95% CI)
All studies	Naked eye	29	23,930	2,140	79 (72–85)	83 (76–88)	0.88 (0.85–0.91)
	Dermoscopy	79	33,749	5,031	86 (83–89)	81 (76–86)	0.91 (0.88–0.93)
All studies	Nonexperts	20	22,580	1,630	82 (73–89)	73 (60–83)	0.85 (0.82–0.88)
	Experts	65	29,767	3,812	84 (79–87)	85 (80–89)	0.91 (0.88–0.93)
All studies	Primary care	10	19,152	867	80 (65–89)	71 (52–85)	0.83 (0.79–0.86)
	Secondary care	87	36,673	5,480	85 (82–88)	82 (77–87)	0.91 (0.88–0.93)
Nonexperts	Naked eye	9	16,304	1,045	78 (60–90)	74 (54–88)	0.83 (0.80–0.86)
	Dermoscopy	11	6,279	585	83 (76–89)	72 (55–84)	0.86 (0.83–0.89)
Experts	Naked eye	16	7,115	922	79 (70–86)	86 (79–91)	0.90 (0.87–0.92)
	Dermoscopy	49	22,652	2,890	85 (79–89)	85 (77–90)	0.91 (0.89–0.94)
Primary care	Naked eye	6	14,822	595	78 (52–92)	74 (43–91)	0.83 (0.80–0.86)
	Dermoscopy	4	4,330	272	82 (74–87)	66 (57–74)	0.83 (0.79–0.86)
Secondary care	Naked eye	19	8,597	1,372	79 (71–86)	85 (78–90)	0.89 (0.86–0.91)
	Dermoscopy	68	28,076	4,108	87 (83–90)	82 (75–87)	0.91 (0.88–0.93)

^aThe number of estimates exceeds the number of studies because multiple estimates are made using dermoscopy with alternative diagnostic algorithms.

CI = confidence interval; sROC = summary receiver operating characteristic.